OS Therapies Receives FDA and MHRA Feedback on OST-HER2 for Metastatic Osteosarcoma

OS Therapies Inc. announced that the FDA granted a Type C meeting to discuss clinical efficacy data endpoints for a BLA under the Accelerated Approval...